S&P 500   3,960.78 (+0.68%)
DOW   33,736.51 (+0.41%)
QQQ   283.07 (+0.91%)
AAPL   142.33 (+0.99%)
MSFT   246.32 (+0.80%)
META   115.37 (+1.26%)
GOOGL   93.94 (-1.05%)
AMZN   90.24 (+2.01%)
TSLA   173.33 (-0.41%)
NVDA   169.76 (+5.31%)
NIO   13.36 (+6.20%)
BABA   94.05 (+6.48%)
AMD   69.86 (-0.40%)
T   19.09 (-1.09%)
MU   55.05 (+2.29%)
CGC   3.00 (-7.41%)
F   13.13 (+0.23%)
GE   83.43 (-1.85%)
DIS   92.37 (+0.24%)
AMC   6.13 (+1.32%)
PYPL   74.30 (-0.16%)
PFE   51.49 (+2.49%)
NFLX   308.71 (+0.09%)
S&P 500   3,960.78 (+0.68%)
DOW   33,736.51 (+0.41%)
QQQ   283.07 (+0.91%)
AAPL   142.33 (+0.99%)
MSFT   246.32 (+0.80%)
META   115.37 (+1.26%)
GOOGL   93.94 (-1.05%)
AMZN   90.24 (+2.01%)
TSLA   173.33 (-0.41%)
NVDA   169.76 (+5.31%)
NIO   13.36 (+6.20%)
BABA   94.05 (+6.48%)
AMD   69.86 (-0.40%)
T   19.09 (-1.09%)
MU   55.05 (+2.29%)
CGC   3.00 (-7.41%)
F   13.13 (+0.23%)
GE   83.43 (-1.85%)
DIS   92.37 (+0.24%)
AMC   6.13 (+1.32%)
PYPL   74.30 (-0.16%)
PFE   51.49 (+2.49%)
NFLX   308.71 (+0.09%)
S&P 500   3,960.78 (+0.68%)
DOW   33,736.51 (+0.41%)
QQQ   283.07 (+0.91%)
AAPL   142.33 (+0.99%)
MSFT   246.32 (+0.80%)
META   115.37 (+1.26%)
GOOGL   93.94 (-1.05%)
AMZN   90.24 (+2.01%)
TSLA   173.33 (-0.41%)
NVDA   169.76 (+5.31%)
NIO   13.36 (+6.20%)
BABA   94.05 (+6.48%)
AMD   69.86 (-0.40%)
T   19.09 (-1.09%)
MU   55.05 (+2.29%)
CGC   3.00 (-7.41%)
F   13.13 (+0.23%)
GE   83.43 (-1.85%)
DIS   92.37 (+0.24%)
AMC   6.13 (+1.32%)
PYPL   74.30 (-0.16%)
PFE   51.49 (+2.49%)
NFLX   308.71 (+0.09%)
S&P 500   3,960.78 (+0.68%)
DOW   33,736.51 (+0.41%)
QQQ   283.07 (+0.91%)
AAPL   142.33 (+0.99%)
MSFT   246.32 (+0.80%)
META   115.37 (+1.26%)
GOOGL   93.94 (-1.05%)
AMZN   90.24 (+2.01%)
TSLA   173.33 (-0.41%)
NVDA   169.76 (+5.31%)
NIO   13.36 (+6.20%)
BABA   94.05 (+6.48%)
AMD   69.86 (-0.40%)
T   19.09 (-1.09%)
MU   55.05 (+2.29%)
CGC   3.00 (-7.41%)
F   13.13 (+0.23%)
GE   83.43 (-1.85%)
DIS   92.37 (+0.24%)
AMC   6.13 (+1.32%)
PYPL   74.30 (-0.16%)
PFE   51.49 (+2.49%)
NFLX   308.71 (+0.09%)
NASDAQ:AIKI

AIkido Pharma - AIKI Stock Forecast, Price & News

$3.57
+0.04 (+1.13%)
(As of 12/8/2022 02:02 PM ET)
Add
Compare
Today's Range
$3.49
$3.57
50-Day Range
$3.42
$7.21
52-Week Range
$3.31
$12.58
Volume
702 shs
Average Volume
26,512 shs
Market Capitalization
$19.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

AIkido Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
348.2% Upside
$16.00 Price Target
Short Interest
Healthy
1.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$558,357 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.70) to ($1.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

152nd out of 1,022 stocks

Commercial Physical Research Industry

6th out of 18 stocks

AIKI stock logo

About AIkido Pharma (NASDAQ:AIKI) Stock

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Stock News Headlines

AIkido Pharma Inc. (NASDAQ:AIKI) Short Interest Update
AIkido Share Repurchase Continues
AIkido Purchases More Shares
Share Repurchase Program Continues
AIkido Pharma Continues Share Repurchase Program
AIkido Pharma Provides Update on Share Repurchase Program
AIkido Pharma Confirms Receipt of Unsolicited Offer
Aikido Pharma Inc
AIkido Pharma regains Nasdaq compliance
AIkido Pharma Inc. Appoints New Director, Soo Yu
Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
AIkido Announces Reverse Stock Split
See More Headlines
Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Company Calendar

Last Earnings
11/10/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AIKI
Employees
4
Year Founded
1967

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+348.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$19.27 per share

Miscellaneous

Free Float
5,013,000
Market Cap
$19.60 million
Optionable
Not Optionable
Beta
0.93

Social Links


Key Executives

  • Mr. Anthony C. Hayes Esq.Mr. Anthony C. Hayes Esq. (Age 54)
    CEO, Principal Financial Officer, Principal Accounting Officer & Director
    Comp: $960k
  • Mr. Darrell Dotson
    VP of Drug Devel. & Gen. Counsel
  • Mr. Carlos Aldavero
    Pres of Dominari Financial













AIKI Stock - Frequently Asked Questions

Should I buy or sell AIkido Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AIkido Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AIKI shares.
View AIKI analyst ratings
or view top-rated stocks.

What is AIkido Pharma's stock price forecast for 2023?

1 brokers have issued 1-year price targets for AIkido Pharma's stock. Their AIKI share price forecasts range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 353.3% from the stock's current price.
View analysts price targets for AIKI
or view top-rated stocks among Wall Street analysts.

How have AIKI shares performed in 2022?

AIkido Pharma's stock was trading at $9.9790 at the start of the year. Since then, AIKI stock has decreased by 64.6% and is now trading at $3.53.
View the best growth stocks for 2022 here
.

Are investors shorting AIkido Pharma?

AIkido Pharma saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 65,200 shares, a drop of 12.7% from the October 31st total of 74,700 shares. Based on an average trading volume of 76,700 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.3% of the company's shares are short sold.
View AIkido Pharma's Short Interest
.

When is AIkido Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our AIKI earnings forecast
.

How were AIkido Pharma's earnings last quarter?

AIkido Pharma Inc. (NASDAQ:AIKI) issued its quarterly earnings data on Thursday, November, 10th. The business services provider reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by $0.40.

When did AIkido Pharma's stock split?

Shares of AIkido Pharma reverse split on the morning of Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of AIkido Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIkido Pharma investors own include Biocept (BIOC), AIM ImmunoTech (AIM), Nuwellis (CHFS), Foresight Autonomous (FRSX), iBio (IBIO), Exela Technologies (XELA), Bionano Genomics (BNGO), Check-Cap (CHEK), Digital Ally (DGLY) and Purple Biotech (KTOV).

What is AIkido Pharma's stock symbol?

AIkido Pharma trades on the NASDAQ under the ticker symbol "AIKI."

Who are AIkido Pharma's major shareholders?

AIkido Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.53%), Two Sigma Advisers LP (1.58%), Dimensional Fund Advisors LP (1.05%), Two Sigma Investments LP (0.98%), Equitec Proprietary Markets LLC (0.36%) and Jane Street Group LLC (0.20%). Insiders that own company stock include Anthony Hayes, Kyle Michael Wool and Soo Yu.
View institutional ownership trends
.

How do I buy shares of AIkido Pharma?

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AIkido Pharma's stock price today?

One share of AIKI stock can currently be purchased for approximately $3.53.

How much money does AIkido Pharma make?

AIkido Pharma (NASDAQ:AIKI) has a market capitalization of $19.38 million and generates $10,000.00 in revenue each year. The business services provider earns $-7,170,000.00 in net income (profit) each year or ($3.8805) on an earnings per share basis.

Does AIkido Pharma have any subsidiaries?
The following companies are subsidiares of AIkido Pharma: Hoth Therapeutics.
Read More
How can I contact AIkido Pharma?

AIkido Pharma's mailing address is ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020. The official website for the company is www.spherix.com. The business services provider can be reached via phone at (112) 745-1374, via email at investorrelations@spherix.com, or via fax at 703-992-9348.

This page (NASDAQ:AIKI) was last updated on 12/8/2022 by MarketBeat.com Staff